Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for post solid organ transplant lymphoproliferative disease
ACTRN12607000190404Phase 2Completed
- Sponsor
- Institut Català d'Oncologia
- Start
- Nov 2000
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by Institut Català d'Oncologia. Primary endpoint: Complete remission rate. Started Nov 2000; status: completed.
02
Drugs
rituximab
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on ACTRN12607000190404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000190404.